The FDA cleared Viridian Therapeutics’ IGF-1R antagonist Lumvoa (veligrotug-vvze) for thyroid eye disease, giving the company its first commercial product and setting up direct competition with Amgen’s Tepezza. Viridian said the label covers both active and chronic phases and that the approval includes statistically significant effects in diplopia outcomes. The company also launched Viridiancares to support payer access and patient onboarding.